Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Details Textual)

Related Party Transactions (Details Textual) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended			0 Months Ended		1 Months Ended	9 Months Ended	1 Months Ended		9 Months Ended		1 Months Ended	0 Months Ended	6 Months Ended	3 Months Ended		9 Months Ended			12 Months Ended			0 Months Ended	1 Months Ended	9 Months Ended
Related Party Transactions (Details Textual) (USD $)	Jul. 07, 2014	Mar. 24, 2014	Apr. 28, 2014	Sep. 30, 2014	Jul. 10, 2014	Jan. 10, 2014 Placement agent [Member]	Dec. 09, 2013 Placement agent [Member]	Aug. 07, 2012 Placement agent [Member]	Sep. 30, 2014 Placement agent [Member]	Dec. 27, 2013 Investors [Member]	Jan. 31, 2014 Common Stock [Member]	Sep. 30, 2014 Common Stock [Member]	Jan. 31, 2014 Common Stock [Member] Placement agent [Member]	Jan. 31, 2014 Warrant [Member]	Jul. 10, 2014 IPO [Member]	Jun. 30, 2014 IPO [Member]	Sep. 30, 2014 MSKCC [Member]	Sep. 30, 2013 MSKCC [Member]	Sep. 30, 2014 MSKCC [Member]	Sep. 30, 2013 MSKCC [Member]	Sep. 30, 2014 MSKCC [Member] Clinical Trial Agreement [Member]	Dec. 31, 2013 MSKCC [Member] Clinical Trial Agreement [Member]	Dec. 31, 2012 MSKCC [Member] Clinical Trial Agreement [Member]	Mar. 27, 2012 MSKCC [Member] Clinical Trial Agreement [Member]	Sep. 04, 2013 SKI [Member] License, Development and Commercialization Agreement [Member]	Jun. 19, 2011 SKI [Member] License, Development and Commercialization Agreement [Member]	Sep. 30, 2014 SKI [Member] License, Development and Commercialization Agreement [Member]
Related Party Transactions (Textual)
Amount paid under agreement in 2011																										$ 50,000
Amount paid under agreement in 2012																										200,000
Amount paid under agreement in 2013																										250,000
Amount owed under agreement from 2011 to 2014																									815,100
Maintenance fees																	26,000	0	197,106	218,604	278,291	81,185				50,000	189,000
Placement agent services fees									400,000
Warrants issued to purchase common stock, shares									68,976
Common stock exercise price per share				$ 9.00					$ 9
Amount paid to each patient after Completing clinical trial																								31,185
Start-up fee for clinical trial																							79,623
Description of receivables of placement agent for services							Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock	Placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent.
Description of warrants receivables by placement							Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable	The placement agent or its designees also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units.
Period of exercise of warrants								Within 6 months of the final closing of the 2012 common stock Offering	5 years
Percentage of solicitation fee								5.00%
Monthly fee for financial advisory services							25,000	25,000
Description of additional receivable by placement agent								The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement.
Warrant held by placement agent to purchase common stock								1,251,015
Royalty description																			Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.
Common stock sold, Shares	61,538		500							554,310	551,810	1,984,524			1,827,123	1,670,000
Warrants granted														137,952
Sale of Stock, Price Per Share					$ 7.50					$ 6.00	$ 6.00			$ 9.00		$ 7.50
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 6.00
Gross proceeds from the sale of securities						3,310,860				3,325,860
Underwriting discount															13,700,000	876,750
Gross proceeds received in Offering						$ 6,636,720									$ 12,600,000	$ 11,451,250
Aggregate offering amount of securities sold to investors		The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.				Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments				Five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share.